# Spatomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spatomics

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Latest round: Angel (Aug 9, 2023)
- Investors on record: 3

## About

Based in Jiangsu, China, and founded in 2022, Nanjing Yuanxing Intelligent Manufacturing Technology Co., Ltd., trading as Spatomics, is a healthcare company focusing on the development of single-cell spatial multi-omics tool platforms. It has commercial collaborations with several spatial histology CROs, reagent companies, etc. The founder and CEO, Rui Zheng, worked at Thermo Fisher and the total revenue of the products he developed has exceeded USD 1 billion. Five members of the company's team hold doctoral degrees. In December 2025, Spatomics raised a venture fundinng from new investors Yihua Capital, Nanjing Jiangbei Tunzhi Biomedical Venture Capital Partnership (Limited Partnership) and returning investor K2VC.

The company is committed to building a core tool platform for single-cell spatial multi-omics. The single-cell spatial multi-omics instrument developed by the company is capable of completing tissue section pre-processing, antigen repair, staining, imaging, and image pre-processing. In terms of performance, it contains the advantages of high sensitivity and high throughput.

The company's revenue is generated by providing end-to-end universal solution for single-cell spatial multi-omics.

## Funding rounds

- Angel, Aug 9, 2023 — Chang'an Capital, K2VC, Shangshi Fund

## Investors

- Chang'an Capital (https://capitalatlas.ai/funds/chang-an-capital) — Angel
- K2VC (https://capitalatlas.ai/funds/k2vc) — Angel
- Shangshi Fund (https://capitalatlas.ai/funds/shangshi-fund) — Angel